ReviewReumatologia2025
Efficacy of biologic and targeted synthetic disease-modifying antirheumatic drugs in non-infectious uveitis in axial spondyloarthropathy and their ocular side effects.
Review in Reumatologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axial spondyloarthropathy (axSpA) belongs to a group of chronic, progressive inflammatory diseases with a variety of clinical manifestations, including musculoskeletal and extra-articular symptoms. The most common extra-articular manifestation in patients with axSpA is uveitis, which usually involves the anterior segment, can be recurring, and is a vision-threatening complication. Ocular complications can result from the disease itself, as well as from the therapy used to treat it. Treatment for axSpA is based on both pharmacological and non-pharmacological management. Biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) are an effective and constantly evolving form of axSpA therapy; however, their application and side effects remain under study. The aim of this article is to summarize current knowledge about the efficacy of biologic and targeted synthetic DMARDs in non-infectious uveitis in axSpA and delineate their effect on the organ of vision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.